Safety Study of HPP593 in Subjects During and After Limb Immobilization
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A Randomized, Double-blind, Placebo Controlled, Phase I Study to Evaluate the Safety and Tolerability of 28 Day Treatment With HPP593 Capsules in Healthy Volunteers During and After Limb Immobilization
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
30 Years to 55 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subjects must be in good health, as determined by medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical test results.
Not restricted to a wheel-chair or confined to a bed.
Weight ≥ 50.0 kg.
BMI between 18 and 27.5 kg/m2, inclusive, at the time of screening.
Any of the following abnormalities at Screening Visit and Baseline: